2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.

Bender, Aaron M; Parr, Lauren C; Livingston, William B; Lindsley, Craig W; Merryman, W David

Bender, Aaron M; Parr, Lauren C; Livingston, William B; Lindsley, Craig W; Merryman, W David.

Afiliación

Bender AM; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Parr LC; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Livingston WB; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Lindsley CW; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Merryman WD; Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37240, United States.

J Med Chem ; 66(16): 11027-11039, 2023 08 24.

Article en En | MEDLINE | ID: mdl-37584406

Asunto(s)

Enfermedades de las Válvulas Cardíacas; Receptor de Serotonina 5-HT2B; Humanos; Serotonina; Fenfluramina; Descubrimiento de Drogas

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor de Serotonina 5-HT2B / Enfermedades de las Válvulas Cardíacas Límite: Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google